Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Large U.S. COVID-19 vaccine trials will exclude pregnant women for now

share with twitter share with LinkedIn share with facebook
07/31/2020 | 10:07pm EDT
FILE PHOTO: Moderna Therapeutics seen during COVID-19 in Massachusetts

The first two COVID-19 vaccines to enter large-scale U.S. trials will not be tested in pregnant women this year, raising questions about how this vulnerable population will be protected from the coronavirus, researchers told Reuters.

Moderna and Pfizer, which has partnered with Germany's BioNTech, this week separately launched clinical trials that use a new and unproven gene-based technology. Both companies are requiring proof of a negative pregnancy test and a commitment to using birth control from women of childbearing age who enroll.

Drugmakers say they first need to make sure the vaccines are safe and effective more generally. In addition, U.S. regulators require that drugmakers conduct safety studies in pregnant animals before the vaccines are tested in pregnant women to ensure they don't harm the fetus or lead to miscarriage.

Bioethicists, vaccine and maternal health experts have argued for years that pregnant women should be included early in trials of pandemic vaccines so they would not need to wait until long after a successful candidate emerges. That debate fell on deaf ears in recent outbreaks of Ebola and Zika, but has taken on new urgency in the era of COVID-19, as studies show pregnant women are at increased risk of severe disease from the new coronavirus.

"It's a problem because if (vaccines) are not tested in pregnancy, then they may not be available or people may not be comfortable offering them," said Dr. Denise Jamieson, chief of gynecology and obstetrics for Emory Healthcare in Atlanta.

According to the 2012 Census, 75.4 million U.S. women were of childbearing age, defined as 15 to 50 years old. Currently, pregnant women are recommended to take flu and whooping cough vaccines and certain others depending on individual circumstances, but none of these have been specifically tested and proven safe for pregnant women.

"We have an enormous number of women of childbearing age and potentially getting pregnant, and what's the safest vaccine for them?" said Dr. Larry Corey, a vaccine expert at Fred Hutchinson Cancer Center in Seattle who is helping oversee vaccine trials conducted by Moderna and other drugmakers in collaboration with the U.S. government.

Doctors may want to see even more data for completely new vaccine technologies, such as those used by Moderna and Pfizer, compared with one that has already been used in pregnant women.

Such differences highlight why "we need multiple vaccines" to best address the needs of specific populations, Corey said.

A PRECEDENT IN PREGNANCY

Johnson & Johnson, which kicked off a small-scale safety trial for its COVID-19 vaccine this week, is using the same underlying technology that it used with its Ebola vaccine, which has been used in 1,000 pregnant women in Democratic Republic of Congo. Larger studies with that vaccine are now under way.

J&J's chief scientific officer, Dr. Paul Stoffels, told Reuters the company has done many years of "extensive" preclinical study with the Ebola vaccine, including on pregnant animals, and "has not see any challenges."

Stoffels said J&J would decide in the next few weeks whether it will include pregnant women in its large Phase 3 late-stage trial for a COVID-19 vaccine due to start in September.

Pfizer expects to start toxicology studies in pregnant animals shortly, with data ready for review by the U.S. Food and Drug Administration in the first quarter of 2021. Studies in pregnant women could start some time afterward.

"We continue to explore potential ways to shorten the time to studies in pregnant women," Dr. Bill Gruber, Pfizer's senior vice president of vaccine clinical research and development, told Reuters.

Of course, unplanned pregnancies can happen even when women are using reliable contraception. Based on past experiences in such trials, Gruber said he expects about 1% of women who receive the vaccine in Pfizer's Phase 2/3 trial, or about 150 women, will become pregnant. Those women and their babies will be followed closely.

Moderna said in an emailed statement that the company launched its safety study in pregnant animals at the end of June and expects results by the end of this year.

"Once we have generated additional safety data for our vaccine, and importantly demonstrated that it is efficacious, we intend to conduct additional studies in this important population," a Moderna spokesperson said.

Sanofi, whose coronavirus vaccine is based on its flu vaccine platform, is doing reproductive toxicology in animals, but those results won't be ready before the start of the company's large Phase 3 trials, expected to start by year-end.

Sanofi may establish a pregnancy registry after the vaccine is approved to track outcomes in pregnant women, as has been done in the past.

Merck & Co said it has not made any decisions yet on when to test its vaccine candidate in pregnant women. Novavax and AstraZeneca Plc declined to comment on their plans.

Dr. Flor Munoz, an expert in maternal use of vaccines at Baylor College of Medicine, said companies have been reluctant to test anything in pregnant women since the 1950s and 60s, after the drug thalidomide, which was used to treat nausea in pregnancy, caused widespread birth defects. She agrees that preliminary testing is needed.

The vaccines "need to be reasonably safe and reasonably effective," she said. "We don't necessarily have to finish the Phase 3 trials."

By Julie Steenhuysen

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.45% 8541 Delayed Quote.10.67%
BIONTECH SE -5.19% 77.08 Delayed Quote.127.51%
JOHNSON & JOHNSON -0.57% 147.55 Delayed Quote.1.73%
MODERNA, INC. -2.69% 73.76 Delayed Quote.277.10%
NOVAVAX, INC. -3.45% 167.5 Delayed Quote.4,108.54%
PFIZER LIMITED -0.70% 4390.9 End-of-day quote.3.95%
PFIZER, INC. -0.47% 38.27 Delayed Quote.-2.32%
SANOFI 0.75% 87.08 Real-time Quote.-3.59%
share with twitter share with LinkedIn share with facebook
Latest news on MODERNA, INC.
05:46aMODERNA : Swiss ink deal with Moderna for 4.5M doses of COVID vaccine
AQ
05:15aTHE LATEST : German state shuts 2 schools after new cases
AQ
05:00aTHE LATEST : Hong Kong offers free testing for all residents
AQ
02:48aAstraZeneca Sets Deal in China Market -- WSJ
DJ
01:39aMODERNA : Swiss government signs agreement with Moderna for COVID-19 vaccine
RE
08/06Health Care Down As Investors Hedge On Vaccine, Deal Outlook -- Health Care R..
DJ
08/06MODERNA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
08/06AstraZeneca Strikes Deal to Produce Covid-19 Vaccine for China
DJ
08/06GLOBAL MARKETS LIVE: Adidas, Metlife, Toyota…
08/06UNIVERSITY OF TEXAS AT AUSTIN : Locking Down Shape-Shifting Spike Protein Aids D..
AQ
More news
Financials (USD)
Sales 2020 330 M - -
Net income 2020 -542 M - -
Net cash 2020 2 228 M - -
P/E ratio 2020 -50,9x
Yield 2020 -
Capitalization 28 680 M 28 680 M -
EV / Sales 2020 80,2x
EV / Sales 2021 5,38x
Nbr of Employees 850
Free-Float 79,7%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 91,63 $
Last Close Price 73,76 $
Spread / Highest target 81,7%
Spread / Average Target 24,2%
Spread / Lowest Target -18,7%
EPS Revisions
Managers
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.277.10%28 680
LONZA GROUP60.76%46 341
CELLTRION, INC.71.82%35 071
IQVIA HOLDINGS INC.4.23%30 802
SEATTLE GENETICS, INC.41.61%28 153
INCYTE CORPORATION11.80%21 268